Market Research Logo

Liquid Biopsy Markets Global Market Size, Strategies and Forecasts 2016 to 2020 including Screening Market Sizing

1. Introduction and Market Definition
1.1 What is Liquid Biopsy?
1.2 The Genetics Revolution
1.3 Market Definition
1.3.1 Volumes
1.3.2 Prices
1.3.3 Revenue Market Size
1.4 Methodology
1.4.1 Authors
1.4.2 Sources
1.5 Liquid Biopsy and Clinical Laboratory Testing – Spending Perspective
1.5.1 U.S. Medicare Expenditures for Clinical Testing
2. Market Overview
2.1 Market Participants
2.1.1 Academic Research Lab
2.1.2 Diagnostic Test Developer
2.1.3 Genomic Instrumentation Supplier
2.1.3.1 Cell Separation and Viewing Instrumentation Supplier
2.1.4 Pharmaceutical/Reagent Supplier
2.1.5 Independent Testing Lab
2.1.6 Public National/regional lab
2.1.7 Hospital lab
2.1.8 Physician Lab
2.1.9 Audit Body
2.1.10 Certification Body
2.2 Conditions Identified with Biopsies
2.2.1 Cancer
2.2.2 Precancerous conditions
2.2.3 Inflammatory condiditons
2.3 Biopsy Sites
2.4 Analysis of Biopsied Material
2.5 Evidence of Cancer - Liquid Biopsy Technology
2.5.1 Liquid Biopsy Technology Overview
2.5.2 Circulating Tumor Cells
2.5.2.1 Types of CTCs
2.5.2.2 CellSearch Detection Method
2.5.2.3 Epic Sciences Detection Method
2.5.2.4 Maintrac Detection Method
2.5.2.5 Other Methods
2.5.3 Circulating Tumor DNA
2.5.4 Exosomes and Micro Vesicles
2.6 Changing the Cancer Treatment Protocol
2.6.1 Issues and Limitations to Liquid Biopsy Adoption
2.6.2 The Cancer Screening Market Opportunity
2.6.2.1 GRAIL – Exploiting the Screening Opportunity
2.6.3 Cancer Management
2.6.3.1 Risk Assessment Role In Cancer Management
2.6.3.2 Therapy Assessment Role In Cancer Management
2.6.3.3 Disease Monitoring Role In Cancer Management
2.6.4 Phases of Adoption – Outlook for Usage
2.6.5 The Promise of Liquid Biopsy
2.7 Industry Structure
2.7.1 Hospital Testing Share
2.7.2 Economies of Scale
2.7.2.1 Hospital vs. Central Lab
2.7.3 Physician Office Lab’s
2.7.4 Physician’s and POCT
2.8 Profiles of Key Liquid Biopsy Companies
2.8.1 AdnaGen (now Qiagen)
2.8.2 Agena Bioscience
2.8.3 Angle plc
2.8.4 ApoCell
2.8.5 Biocept
2.8.6 BioFluidica
2.8.7 Bio-Rad Laboratories
2.8.8 Boreal Genomics
2.8.10 Chronix Biomedical
2.8.11 Clearbridge BioMedics
2.8.12 Cynvenio
2.8.13 Cytolumina Technologies Corp
2.8.14 CytoTrack
2.8.15 Diagnologix LLC
2.8.16 Epic Sciences
2.8.17 Exosome Diagnostics
2.8.18 Exosome Sciences
2.8.19 Fluidigm Corp
2.8.20 Fluxion Biosciences
2.8.21 Genomic Health
2.8.39 GRAIL
2.8.22 Guardant Health
2.8.23 HansaBiomed
2.8.23 Horizon Discovery
2.8.24 iCellate
2.8.25 Illumina
2.8.26 Inivata
2.8.27 Janssen Diagnostics
2.8.28 Molecular MD
2.8.29 Myriad Genetics
2.8.30 Natera
2.8.31 New Oncology
2.8.32 Personal Genome Diagnostics
2.8.33 RainDance Technologies
2.8.34 Rarecells SAS
2.8.35 Silicon Biosystems
2.8.36 Sysmex Inostics
2.8.37 SRI International
2.8.38 Trovagene
3. Market Trends
3.1 Factors Driving Growth
3.1.1 Non Invasive Game Changer
3.1.2 Lower Cost
3.1.3 Greater Accuracy.
3.1.4 Wide Range of Potential Uses
3.1.5 Aging Population
3.2 Factors Limiting Growth
3.2.1 Lower prices
3.2.2 Lack of Standards.
3.2.3 Protocol Resistance.
3.2.4 Initial Adoption Has No Cost Savings
3.3 Instrumentation and Automation
3.3.1 Instruments Key to Market Share
3.3.2 Bioinformatics Plays a Role.
3.4 Diagnostic Technology Development
3.4.1 Next Generation Sequencing Fuels a Revolution
3.4.2 Impact of NGS on pricing
3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment
3.4.4 CGES Testing, A Brave New World
3.4.5 Biochips/Giant magneto resistance based assay
4. Liquid Biopsy Recent Developments
4.1 Recent Developments – Importance and How to Use This Section
4.1.1 Importance of These Developments
4.1.2 How to Use This Section
4.2 Illumina Forms GRAIL to Enable Early Cancer Detection via Liquid Biopsy
4.3 ASCO: Researchers Present Advances, Ongoing Challenges in Liquid Biopsy
4.4 Guardant Health, SWOG Partner on Prospective NSCLC Liquid Biopsy Study
4.5 Qiagen Expands CDx Deal with Tokai; Acquires CTC Assets from AdnaGen
4.6 Biodesix's GeneStrat Liquid Biopsy Lung Cancer Test
4.7 Baylor, TGen Collaborate on Personalized Cancer Treatment Options
4.8 Liquid Biopsy Firm Resolution Bio Gets CLIA Certification for Lab
4.9 Broad Institute Lands $10M Gift to Study Cancer Drug Resistance
4.10 Biocept Q1 Revenues Rise With Test Volume Growth
4.11 CRUK Manchester Institute Joins European Consortium Validating Blood-based Cancer Biomarkers
4.12 New Oncology Closes Financing Round to Promote Genetic Testing from Blood
4.13 Cynvenio to present new clinical data
4.14 EKF, Angle Collaborate for Liquid Biopsy Development
4.15 Trovagene Collaborates with UCSD for EGFR Monitoring in Lung Cancer
4.16 AstraZeneca Initiates CDx Partnerships with Roche, Qiagen
4.17 Horizon, LGC Awarded Research Grant for Cancer Diagnostics
4.18 Merck Serono and Sysmex Inostics Announce Testing Center
4.19 Agena Bioscience Launches Smaller Format MassArray
4.20 Personal Genome Diagnostics Aims for FDA Clearance
4.21 HTG Molecular Diagnostics Files for IPO of up to $60M
4.22 Genomic Health Reports 5 Percent Revenue Growth in Third Quarter
4.23 Biocept, Rosetta Genomics Partner to Profile microRNAs from CTCs
4.24 Inivata Raises $6.6M to Develop ctDNA Assays
4.25 Epic Sciences Raises $30M in Private Financing
4.26 New Release in Line of Liquid Biopsy CLIA Tests
4.27 Collaborators Publish Data on Resolution Bio Liquid Biopsy Test
4.27 Trovagene's Urine-Based Liquid Biopsy Platform Demonstrated in Field
4.28 FDA Sends Pathway Genomics Untitled Letter Over Liquid Biopsy Test
4.29 DNA in blood can track cancer development, response in real time
4.30 Cynvenio Clinical Trial Supports Multi-Template Liquid Biopsy Sequencing
4.31 Startup AccuraGen to Tap China Liquid Biopsy Market With 61-Gene Assay
4.32 Sysmex Corporation and Clearbridge BioMedics to Jointly Develop New Liquid Biopsy System
4.33 MDxHealth Launches SelectMDx "Liquid Biopsy" Test in the United States
4.34 GATC Biotech’s Liquid Biopsy Testing Takes Cost Lead
4.35 Liquid Biotech USA, Inc. Announces Completion of Clinical Study
4.36 Liquid biopsies more effective in some cases than tissue biopsies
4.37 Cancer Genetics, Inc. and ApoCell Announce Partnership for Rare Cell Capture and Detection
4.38 Exosome Diagnostics Launches Liquid Biopsy Test to Rule Out High-Grade Prostate Cancer
4.39 Liquid Biopsy Tests Partially Validated
4.40 FDA Approves Liquid Biopsy
4.41 Liquid Biopsy Predicts Colon Cancer Recurrence
4.42 WaveSense Receives CE-IVD Mark for Cell Enrichment Platform
4.43 For Liquid Biopsy, Size Matters
4.44 Liquid biopsy startup Freenome lands $5.5 million led by Andreessen Horowitz
4.45 Trovagene, USC Collaborate on Deployment of Urine-Based Liquid Biopsy Test
4.46 Circulogene liquid biopsy detects new tumor mass earlier than current imaging methods
5. Country Market Sizes – North America
5.1 United States of America
5.1.1 Lung Cancer Testing – Volumes, Prices, Revenues
5.1.2 Breast Cancer Testing – Volumes, Prices, Revenues
5.1.3 Colorectal Cancer Testing – Volumes, Prices, Revenues
5.1.4 Prostate Cancer Testing – Volumes, Prices, Revenues
5.1.5 Other Cancer Testing – Volumes, Prices, Revenues
5.1.6 All Liquid Biopsy Total – Volumes, Prices, Revenues
5.2 Canada
5.2.1 Lung Cancer Testing – Volumes, Prices, Revenues
5.2.2 Breast Cancer Testing – Volumes, Prices, Revenues
5.2.3 Colorectal Cancer Testing – Volumes, Prices, Revenues
5.2.4 Prostate Cancer Testing – Volumes, Prices, Revenues
5.2.5 Other Cancer Testing – Volumes, Prices, Revenues
5.2.6 All Liquid Biopsy Total – Volumes, Prices, Revenues
6. Country Markets – Europe
6.1 France
6.1.1 Lung Cancer Testing – Volumes, Prices, Revenues
6.1.2 Breast Cancer Testing – Volumes, Prices, Revenues
6.1.3 Colorectal Cancer Testing – Volumes, Prices, Revenues
6.1.4 Prostate Cancer Testing – Volumes, Prices, Revenues
6.1.5 Other Cancer Testing – Volumes, Prices, Revenues
6.1.6 All Liquid Biopsy Total – Volumes, Prices, Revenues
6.2 Germany
6.2.1 Lung Cancer Testing – Volumes, Prices, Revenues
6.2.2 Breast Cancer Testing – Volumes, Prices, Revenues
6.2.3 Colorectal Cancer Testing – Volumes, Prices, Revenues
6.2.4 Prostate Cancer Testing – Volumes, Prices, Revenues
6.2.5 Other Cancer Testing – Volumes, Prices, Revenues
6.2.6 All Liquid Biopsy Total – Volumes, Prices, Revenues
6.3 United Kingdom
6.3.1 Lung Cancer Testing – Volumes, Prices, Revenues
6.3.2 Breast Cancer Testing – Volumes, Prices, Revenues
6.3.3 Colorectal Cancer Testing – Volumes, Prices, Revenues
6.3.4 Prostate Cancer Testing – Volumes, Prices, Revenues
6.3.5 Other Cancer Testing – Volumes, Prices, Revenues
6.3.6 All Liquid Biopsy Total – Volumes, Prices, Revenues
6.4 Spain
6.4.1 Lung Cancer Testing – Volumes, Prices, Revenues
6.4.2 Breast Cancer Testing – Volumes, Prices, Revenues
6.4.3 Colorectal Cancer Testing – Volumes, Prices, Revenues
6.4.4 Prostate Cancer Testing – Volumes, Prices, Revenues
6.4.5 Other Cancer Testing – Volumes, Prices, Revenues
6.4.6 All Liquid Biopsy Total – Volumes, Prices, Revenues
6.5 Italy
6.5.1 Lung Cancer Testing – Volumes, Prices, Revenues
6.5.2 Breast Cancer Testing – Volumes, Prices, Revenues
6.5.3 Colorectal Cancer Testing – Volumes, Prices, Revenues
6.5.4 Prostate Cancer Testing – Volumes, Prices, Revenues
6.5.5 Other Cancer Testing – Volumes, Prices, Revenues
6.5.6 All Liquid Biopsy Total – Volumes, Prices, Revenues
6.6 Russia
6.6.1 Lung Cancer Testing – Volumes, Prices, Revenues
6.6.2 Breast Cancer Testing – Volumes, Prices, Revenues
6.6.3 Colorectal Cancer Testing – Volumes, Prices, Revenues
6.6.4 Prostate Cancer Testing – Volumes, Prices, Revenues
6.6.5 Other Cancer Testing – Volumes, Prices, Revenues
6.6.6 All Liquid Biopsy Total – Volumes, Prices, Revenues
6.7 Remainder of Europe and Former Soviet Union
6.7.1 Lung Cancer Testing – Volumes, Prices, Revenues
6.7.2 Breast Cancer Testing – Volumes, Prices, Revenues
6.7.3 Colorectal Cancer Testing – Volumes, Prices, Revenues
6.7.4 Prostate Cancer Testing – Volumes, Prices, Revenues
6.7.5 Other Cancer Testing – Volumes, Prices, Revenues
6.7.6 All Liquid Biopsy Total – Volumes, Prices, Revenues
7. Country Markets – Asia Pacific
7.1 China
7.1.1 Lung Cancer Testing – Volumes, Prices, Revenues
7.1.2 Breast Cancer Testing – Volumes, Prices, Revenues
7.1.3 Colorectal Cancer Testing – Volumes, Prices, Revenues
7.1.4 Prostate Cancer Testing – Volumes, Prices, Revenues
7.1.5 Other Cancer Testing – Volumes, Prices, Revenues
7.1.6 All Liquid Biopsy Total – Volumes, Prices, Revenues
7.2 Japan
7.2.1 Lung Cancer Testing – Volumes, Prices, Revenues
7.2.2 Breast Cancer Testing – Volumes, Prices, Revenues
7.2.3 Colorectal Cancer Testing – Volumes, Prices, Revenues
7.2.4 Prostate Cancer Testing – Volumes, Prices, Revenues
7.2.5 Other Cancer Testing – Volumes, Prices, Revenues
7.2.6 All Liquid Biopsy Total – Volumes, Prices, Revenues
7.3 South Korea
7.3.1 Lung Cancer Testing – Volumes, Prices, Revenues
7.3.2 Breast Cancer Testing – Volumes, Prices, Revenues
7.3.3 Colorectal Cancer Testing – Volumes, Prices, Revenues
7.3.4 Prostate Cancer Testing – Volumes, Prices, Revenues
7.3.5 Other Cancer Testing – Volumes, Prices, Revenues
7.3.6 All Liquid Biopsy Total – Volumes, Prices, Revenues
7.4 India
7.4.1 Lung Cancer Testing – Volumes, Prices, Revenues
7.4.2 Breast Cancer Testing – Volumes, Prices, Revenues
7.4.3 Colorectal Cancer Testing – Volumes, Prices, Revenues
7.4.4 Prostate Cancer Testing – Volumes, Prices, Revenues
7.4.5 Other Cancer Testing – Volumes, Prices, Revenues
7.4.6 All Liquid Biopsy Total – Volumes, Prices, Revenues
7.5 Australia
7.5.1 Lung Cancer Testing – Volumes, Prices, Revenues
7.5.2 Breast Cancer Testing – Volumes, Prices, Revenues
7.5.3 Colorectal Cancer Testing – Volumes, Prices, Revenues
7.5.4 Prostate Cancer Testing – Volumes, Prices, Revenues
7.5.5 Other Cancer Testing – Volumes, Prices, Revenues
7.5.6 All Liquid Biopsy Total – Volumes, Prices, Revenues
7.6 Rest of Asia Pacific
7.6.1 Lung Cancer Testing – Volumes, Prices, Revenues
7.6.2 Breast Cancer Testing – Volumes, Prices, Revenues
7.6.3 Colorectal Cancer Testing – Volumes, Prices, Revenues
7.6.4 Prostate Cancer Testing – Volumes, Prices, Revenues
7.6.5 Other Cancer Testing – Volumes, Prices, Revenues
7.6.6 All Liquid Biopsy Total – Volumes, Prices, Revenues
8. Country Markets – Latin America, Africa & The Middle East
8.1 Brazil
8.1.1 Lung Cancer Testing – Volumes, Prices, Revenues
8.1.2 Breast Cancer Testing – Volumes, Prices, Revenues
8.1.3 Colorectal Cancer Testing – Volumes, Prices, Revenues
8.1.4 Prostate Cancer Testing – Volumes, Prices, Revenues
8.1.5 Other Cancer Testing – Volumes, Prices, Revenues
8.1.6 All Liquid Biopsy Total – Volumes, Prices, Revenues
8.2 Mexico
8.2.1 Lung Cancer Testing – Volumes, Prices, Revenues
8.2.2 Breast Cancer Testing – Volumes, Prices, Revenues
8.2.3 Colorectal Cancer Testing – Volumes, Prices, Revenues
8.2.4 Prostate Cancer Testing – Volumes, Prices, Revenues
8.2.5 Other Cancer Testing – Volumes, Prices, Revenues
8.2.6 All Liquid Biopsy Total – Volumes, Prices, Revenues
8.3 Rest of Latin America
8.3.1 Lung Cancer Testing – Volumes, Prices, Revenues
8.3.2 Breast Cancer Testing – Volumes, Prices, Revenues
8.3.3 Colorectal Cancer Testing – Volumes, Prices, Revenues
8.3.4 Prostate Cancer Testing – Volumes, Prices, Revenues
8.3.5 Other Cancer Testing – Volumes, Prices, Revenues
8.3.6 All Liquid Biopsy Total – Volumes, Prices, Revenues
8.4 Africa and The Middle East
8.4.1 Lung Cancer Testing – Volumes, Prices, Revenues
8.4.2 Breast Cancer Testing – Volumes, Prices, Revenues
8.4.3 Colorectal Cancer Testing – Volumes, Prices, Revenues
8.4.4 Prostate Cancer Testing – Volumes, Prices, Revenues
8.4.5 Other Cancer Testing – Volumes, Prices, Revenues
8.4.6 All Liquid Biopsy Total – Volumes, Prices, Revenues
9. Global Market Summary
9.1 Global
9.1.1 Lung Cancer Testing – Volumes, Prices, Revenues
9.1.2 Breast Cancer Testing – Volumes, Prices, Revenues
9.1.3 Colorectal Cancer Testing – Volumes, Prices, Revenues
9.1.4 Prostate Cancer Testing – Volumes, Prices, Revenues
9.1.5 Other Cancer Testing – Volumes, Prices, Revenues
9.1.6 All Liquid Biopsy Total – Volumes, Prices, Revenues
10. Potential Market Opportunity Sizes
10.1 Cancer Screening by Country: Lung, Breast & Colorectal
10.2 Cancer Screening by Country: Prostate, Other Cancer & All Cancer
10.3 Potential Market Size - Cancer Diagnosis
10.4 Potential Market Size - Cancer Management
Appendices
I. United States Medicare System: January 2015 Clinical Laboratory Fees Schedule – National Limit and Midpoint
II. FDA Approved Human Genetic Tests
III. FDA Approved Pharmacogenomics Tests
Table of Tables
Table 1 Medicare Clinical Lab Expenditures Actual & Forecast 2004 to 2020 ($Billion)
Table 2 Market Players by Type
Table 3 Biopsy Sites
Table 4 Advantages of Liquid Biopsy in Screening Market
Table 5 Five Factors Driving Growth
Table 6 Four Factors Limiting Growth
Table 7 Key Diagnostic Laboratory Technology Trends
Table 8 Next Generation Sequencing Technologies – Speed and Cost
Table 9 Lung Cancer Testing - Volume Price and Revenue Forecast
Table 10 Breast Cancer Testing - Volume Price and Revenue Forecast
Table 11 Colorectal Cancer Testing - Volume Price and Revenue Forecast
Table 12 Prostate Cancer Testing - Volume Price and Revenue Forecast
Table 13 Other Cancer Testing - Volume Price and Revenue Forecast
Table 14 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
Table 15 Lung Cancer Testing - Volume Price and Revenue Forecast
Table 16 Breast Cancer Testing - Volume Price and Revenue Forecast
Table 17 Colorectal Cancer Testing - Volume Price and Revenue Forecast
Table 18 Prostate Cancer Testing - Volume Price and Revenue Forecast
Table 19 Other Cancer Testing - Volume Price and Revenue Forecast
Table 20 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
Table 21 Lung Cancer Testing - Volume Price and Revenue Forecast
Table 22 Breast Cancer Testing - Volume Price and Revenue Forecast
Table 23 Colorectal Cancer Testing - Volume Price and Revenue Forecast
Table 24 Prostate Cancer Testing - Volume Price and Revenue Forecast
Table 25 Other Cancer Testing - Volume Price and Revenue Forecast
Table 26 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
Table 27 Lung Cancer Testing - Volume Price and Revenue Forecast
Table 28 Breast Cancer Testing - Volume Price and Revenue Forecast
Table 29 Colorectal Cancer Testing - Volume Price and Revenue Forecast
Table 30 Prostate Cancer Testing - Volume Price and Revenue Forecast
Table 31 Other Cancer Testing - Volume Price and Revenue Forecast
Table 32 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
Table 33 Lung Cancer Testing - Volume Price and Revenue Forecast
Table 34 Breast Cancer Testing - Volume Price and Revenue Forecast
Table 35 Colorectal Cancer Testing - Volume Price and Revenue Forecast
Table 36 Prostate Cancer Testing - Volume Price and Revenue Forecast
Table 37 Other Cancer Testing - Volume Price and Revenue Forecast
Table 38 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
Table 39 Lung Cancer Testing - Volume Price and Revenue Forecast
Table 40 Breast Cancer Testing - Volume Price and Revenue Forecast
Table 41 Colorectal Cancer Testing - Volume Price and Revenue Forecast
Table 42 Prostate Cancer Testing - Volume Price and Revenue Forecast
Table 43 Other Cancer Testing - Volume Price and Revenue Forecast
Table 44 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
Table 45 Lung Cancer Testing - Volume Price and Revenue Forecast
Table 46 Breast Cancer Testing - Volume Price and Revenue Forecast
Table 47 Colorectal Cancer Testing - Volume Price and Revenue Forecast
Table 48 Prostate Cancer Testing - Volume Price and Revenue Forecast
Table 49 Other Cancer Testing - Volume Price and Revenue Forecast
Table 50 All Liquid Biopsy Testing - Volume, Price and Revenue Forecast
Table 51 Lung Cancer Testing - Volume Price and Revenue Forecast
Table 52 Breast Cancer Testing - Volume Price and Revenue Forecast
Table 53 Colorectal Cancer Testing - Volume Price and Revenue Forecast
Table 54 Prostate Cancer Testing - Volume Price and Revenue Forecast
Table 55 Other Cancer Testing - Volume Price and Revenue Forecast
Table 56 All Liquid Biopsy - Volume Price and Revenue Forecast
Table 57 Lung Cancer Testing - Volume Price and Revenue Forecast
Table 58 Breast Cancer Testing - Volume Price and Revenue Forecast
Table 59 Colorectal Cancer Testing - Volume Price and Revenue Forecast
Table 60 Prostate Cancer Testing - Volume Price and Revenue Forecast
Table 61 Other Cancer Testing - Volume Price and Revenue Forecast
Table 62 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
Table 63 Lung Cancer Testing - Volume Price and Revenue Forecast
Table 64 Breast Cancer Testing - Volume Price and Revenue Forecast
Table 65 Colorectal Cancer Testing - Volume Price and Revenue Forecast
Table 66 Prostate Cancer Testing - Volume Price and Revenue Forecast
Table 67 Other Cancer Testing - Volume Price and Revenue Forecast
Table 68 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
Table 69 Lung Cancer Testing - Volume Price and Revenue Forecast
Table 70 Breast Cancer Testing - Volume Price and Revenue Forecast
Table 71 Colorectal Cancer Testing - Volume Price and Revenue Forecast
Table 72 Prostate Cancer Testing - Volume Price and Revenue Forecast
Table 73 Other Cancer Testing - Volume Price and Revenue Forecast
Table 74 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
Table 75 Lung Cancer Testing - Volume Price and Revenue Forecast
Table 76 Breast Cancer Testing - Volume Price and Revenue Forecast
Table 77 Colorectal Cancer Testing - Volume Price and Revenue Forecast
Table 78 Prostate Cancer Testing - Volume Price and Revenue Forecast
Table 79 Other Cancer Testing - Volume Price and Revenue Forecast
Table 80 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
Table 81 Lung Cancer Testing - Volume Price and Revenue Forecast
Table 82 Breast Cancer Testing - Volume Price and Revenue Forecast
Table 83 Colorectal Cancer Testing - Volume Price and Revenue Forecast
Table 84 Prostate Cancer Testing - Volume Price and Revenue Forecast
Table 85 Other Cancer Testing - Volume Price and Revenue Forecast
Table 86 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
Table 87 Lung Cancer Testing - Volume Price and Revenue Forecast
Table 88 Breast Cancer Testing - Volume Price and Revenue Forecast
Table 89 Colorectal Cancer Testing - Volume Price and Revenue Forecast
Table 90 Prostate Cancer Testing - Volume Price and Revenue Forecast
Table 91 Other Cancer Testing - Volume Price and Revenue Forecast
Table 92 All Liquid Biopsy Testing - Volume, Price and Revenue Forecast
Table 93 Lung Cancer Testing - Volume Price and Revenue Forecast
Table 94 Breast Cancer Testing - Volume Price and Revenue Forecast
Table 95 Colorectal Cancer Testing - Volume Price and Revenue Forecast
Table 96 Prostate Cancer Testing - Volume Price and Revenue Forecast
Table 97 Other Cancer Testing - Volume Price and Revenue Forecast
Table 98 All Liquid Biopsy - Volume Price and Revenue Forecast
Table 99 Lung Cancer Testing - Volume Price and Revenue Forecast
Table 100 Breast Cancer Testing - Volume Price and Revenue Forecast
Table 101 Colorectal Cancer Testing - Volume Price and Revenue Forecast
Table 102 Prostate Cancer Testing - Volume Price and Revenue Forecast
Table 103 Other Cancer Testing - Volume Price and Revenue Forecast
Table 104 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
Table 105 Lung Cancer Testing - Volume Price and Revenue Forecast
Table 106 Breast Cancer Testing - Volume Price and Revenue Forecast
Table 107 Colorectal Cancer Testing - Volume Price and Revenue Forecast
Table 108 Prostate Cancer Testing - Volume Price and Revenue Forecast
Table 109 Other Cancer Testing - Volume Price and Revenue Forecast
Table 110 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
Table 111 Lung Cancer Testing - Volume Price and Revenue Forecast
Table 112 Breast Cancer Testing - Volume Price and Revenue Forecast
Table 113 Colorectal Cancer Testing - Volume Price and Revenue Forecast
Table 114 Prostate Cancer Testing - Volume Price and Revenue Forecast
Table 115 Other Cancer Testing - Volume Price and Revenue Forecast
Table 116 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
Table 117 Lung Cancer Testing - Volume Price and Revenue Forecast
Table 118 Breast Cancer Testing - Volume Price and Revenue Forecast
Table 119 Colorectal Cancer Testing - Volume Price and Revenue Forecast
Table 120 Prostate Cancer Testing - Volume Price and Revenue Forecast
Table 121 Other Cancer Testing - Volume Price and Revenue Forecast
Table 122 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
Table 123 Lung Cancer Testing - Volume Price and Revenue Forecast
Table 124 Breast Cancer Testing - Volume Price and Revenue Forecast
Table 125 Colorectal Cancer Testing - Volume Price and Revenue Forecast
Table 126 Prostate Cancer Testing - Volume Price and Revenue Forecast
Table 127 Other Cancer Testing - Volume Price and Revenue Forecast
Table 128 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
Table 129 Potential Screening Market: Lung, Breast & Colorectal
Table 130 Potential Screening Market: Prostate, Other & All
Table 131 Potential Cancer Diagnosis Market Size
Table 132 Potential Cancer Management Market Size
Table 133 2015 Clinical Lab Fee Schedule
Liquid Biopsy Markets Page | 14
Figure 1 Medicare Clinical Lab Expenditures 2004 to 2020 ($Million)
Figure 2 Comparison of Liquid Biopsy Classes
Figure 3 Characteristics of Different Vesicle Types
Figure 4 Percentage of World Population Over 65

Liquid Biopsy Markets Global Market Size, Strategies and Forecasts 2016 to 2020 including Screening Market Sizing

The Diagnostic, Monitoring and Screening Test opportunities are explored.

A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. The technology creates new markets for cancer screening tests.

GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers. The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has outstanding growth potential. The impact on the health care industry is enormous. The report forecasts the market size out to 2020. In addition, the report looks at potential market sizes by country, by cancer and by the three different opportunities: detection, management and screening.

Use independent research that makes you the expert. Get our research team working for you by ordering this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. Get an extra player on your team as unlimited assistance and breakout data is included with your purchase.

Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.

The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate and Other Cancers.

What is the size of the huge screening opportunity? They are all listed in Chapter 10.

All report data is available in Excel format on request. Make investment decisions and valuations with confidence using the latest data.


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;